Acquisition Completed
Eli Lilly and Company acquisition of 4E Therapeutics
Announced 16 Jun 2026
Advisers
4E Therapeutics
Target
- Financial adviser
- Aquilo Partners LP
- Legal adviser
Eli Lilly and Company
Acquirer
Not disclosed
- Target
- 4E Therapeutics
- Acquirer
- Eli Lilly and Company
- Target based in
- United States
- Buyer based in
- United States
- Completed
- 16 Jun 2026
- Sector
- Biotech
- Tags
- Biotech, Drug Development
In the league tables
Similar deals
- Leyden Labs acquisition of RIGImmune Sep 2026 · Biotech
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- Novo Nordisk stake in Orbis Medicines Sep 2026 · Biotech
- Eli Lilly and Company acquisition of Merida Biosciences Aug 2026 · US$2.9bn · Biotech
- Werewolf Therapeutics and Ambros Therapeutics merger Aug 2026 · US$500m · Biotech